Compare RGEN & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGEN | SF |
|---|---|---|
| Founded | 1981 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 12.7B |
| IPO Year | 1995 | N/A |
| Metric | RGEN | SF |
|---|---|---|
| Price | $117.22 | $73.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $173.09 | $89.17 |
| AVG Volume (30 Days) | 856.6K | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.92% |
| EPS Growth | ★ 286.96 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $141,236,000.00 | N/A |
| Revenue This Year | $14.31 | $17.04 |
| Revenue Next Year | $14.41 | $7.61 |
| P/E Ratio | $132.85 | ★ $20.53 |
| Revenue Growth | ★ 35.10 | N/A |
| 52 Week Low | $102.97 | $69.31 |
| 52 Week High | $175.77 | $134.74 |
| Indicator | RGEN | SF |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 26.30 |
| Support Level | $112.53 | N/A |
| Resistance Level | $132.51 | $116.74 |
| Average True Range (ATR) | 4.75 | 1.93 |
| MACD | 0.65 | 1.49 |
| Stochastic Oscillator | 24.95 | 50.09 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.